Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 14/20 | 0.45 |
| ▸ | GSK3B | P49841 | 14/20 | 0.45 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 2/20 | 0.33 |
| ▸ | JAK3 | P52333 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11917620 | 0.88 | GSK3A (0.43) | GSK3AGSK3BGRM4PIK3CACYP1A2 | |
| SCHEMBL11917623 | 0.87 | GSK3A (0.42) | GSK3AGSK3BGRM4PIK3CAJAK2 | |
| SCHEMBL11917622 | 0.82 | GSK3A (0.43) | GSK3AGSK3BGRM4PIK3CACYP1A2 | |
| SCHEMBL12303166 | 0.81 | GSK3A (0.44) | GSK3AGSK3BCYP1A2 | |
| SCHEMBL915313 | 0.81 | GSK3A (0.71) | GSK3AGSK3BPIK3CAJAK2 | |
| SCHEMBL947431 | 0.79 | GSK3A (0.52) | GSK3AGSK3BCYP1A2 | |
| SCHEMBL11917633 | 0.79 | GSK3A (0.72) | GSK3AGSK3BGRM4 | |
| SCHEMBL11917613 | 0.75 | GSK3A (0.39) | GSK3AGSK3BGRM4PIK3CACYP1A2 | |
| SCHEMBL2438325 | 0.74 | PDPK1 (0.40) | GSK3AGSK3BGRM4PIK3CACYP1A2 | |
| SCHEMBL14070089 | 0.73 | GRM4 (0.39) | GSK3AGSK3BGRM4PIK3CACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242272-B2 | Process for preparing 5-fluoro-1H-pyrazolo [3,4-B] pyridin-3-amine and derivatives thereof | VERTEX PHARMACEUTICALS INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20100184980-A1 | Process for Preparing 5-Fluoro-1H-Pyrazolo [3,4-b] Pyridin-3-amine and Derivatives Thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184980-A1 | Process for Preparing 5-Fluoro-1H-Pyrazolo [3,4-b] Pyridin-3-amine and Derivatives Thereof | GSK3B, GSK3A, GSKIP | GSK3A 2/4885GSK3B 1/4885GRM4 2769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.